NTRK1 and non-small cell lung carcinoma: Oncogenic addiction to EGFR mutations is commonly found in NSCLC patients and EGFR-mutated cell lines are vulnerable to genetic knockout or selective receptor tyrosine kinase inhibitors, such as Erlotinib (Tarceva)10.